AU595467B2 - Azolidinedione derivatives - Google Patents

Azolidinedione derivatives Download PDF

Info

Publication number
AU595467B2
AU595467B2 AU21841/88A AU2184188A AU595467B2 AU 595467 B2 AU595467 B2 AU 595467B2 AU 21841/88 A AU21841/88 A AU 21841/88A AU 2184188 A AU2184188 A AU 2184188A AU 595467 B2 AU595467 B2 AU 595467B2
Authority
AU
Australia
Prior art keywords
compound
product
spiro
methyl
mole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU21841/88A
Other languages
English (en)
Other versions
AU2184188A (en
Inventor
Steven W. Goldstein
Reinhard Sarges
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Publication of AU2184188A publication Critical patent/AU2184188A/en
Application granted granted Critical
Publication of AU595467B2 publication Critical patent/AU595467B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU21841/88A 1987-09-04 1988-09-02 Azolidinedione derivatives Ceased AU595467B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USUS8702196 1987-09-04
PCT/US1987/002196 WO1989001775A1 (en) 1987-09-04 1987-09-04 Azolidinedione derivatives

Publications (2)

Publication Number Publication Date
AU2184188A AU2184188A (en) 1989-03-09
AU595467B2 true AU595467B2 (en) 1990-03-29

Family

ID=22202540

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21841/88A Ceased AU595467B2 (en) 1987-09-04 1988-09-02 Azolidinedione derivatives

Country Status (21)

Country Link
EP (1) EP0306251A3 (enExample)
JP (1) JPS6471882A (enExample)
KR (1) KR900008841B1 (enExample)
CN (1) CN1022325C (enExample)
AU (1) AU595467B2 (enExample)
CS (1) CS273186B2 (enExample)
DD (1) DD273381A5 (enExample)
DK (1) DK488688A (enExample)
EG (1) EG18591A (enExample)
FI (1) FI901087A0 (enExample)
HU (1) HU204832B (enExample)
IL (1) IL87590A (enExample)
MX (1) MX12896A (enExample)
MY (1) MY103765A (enExample)
NO (1) NO901016L (enExample)
PH (1) PH24957A (enExample)
PL (1) PL156798B1 (enExample)
PT (1) PT88407B (enExample)
WO (1) WO1989001775A1 (enExample)
YU (1) YU46863B (enExample)
ZA (1) ZA886507B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU603301B2 (en) * 1988-07-27 1990-11-08 Pfizer Inc. Novel resolution process for racemic spiro-hydantoins

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068333A (en) * 1990-03-07 1991-11-26 Pfizer Inc. 6-chloro-3,4-dihydro-pyrano [2,3-b]pyridines having the R configuration
DE10210195B4 (de) 2002-03-07 2005-12-15 Schwarz Pharma Ag Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz
KR101308227B1 (ko) * 2005-04-21 2013-09-13 이시하라 산교 가부시끼가이샤 니코틴산 유도체 또는 그의 염의 제조 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2943177A (en) * 1976-10-18 1979-04-12 Pfizer Inc. Spiro hydantion derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176185A (en) * 1979-01-22 1979-11-27 Pfizer Inc. Spiro-quinolylhydantoins
US4226875A (en) * 1979-04-02 1980-10-07 Pfizer Inc. Novel spiro-oxazolidinediones
FR2455046A1 (fr) * 1979-04-25 1980-11-21 Science Union & Cie Nouvelles hydantoines, leur procede de preparation et leur emploi comme medicament
US4235911A (en) * 1979-06-13 1980-11-25 Pfizer Inc. Hydantoin derivatives
US4248882A (en) * 1980-02-12 1981-02-03 Pfizer Inc. Treating diabetes-associated complications with hydantoin amines
ATE11781T1 (de) * 1981-05-13 1985-02-15 Imperial Chemical Industries Plc Pharmazeutische zubereitungen, die spirosuccinimidderivate enthalten.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2943177A (en) * 1976-10-18 1979-04-12 Pfizer Inc. Spiro hydantion derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU603301B2 (en) * 1988-07-27 1990-11-08 Pfizer Inc. Novel resolution process for racemic spiro-hydantoins

Also Published As

Publication number Publication date
CS591188A2 (en) 1990-06-13
PL274504A1 (en) 1989-05-02
KR890005112A (ko) 1989-05-11
JPS6471882A (en) 1989-03-16
PT88407B (pt) 1992-10-30
NO901016D0 (no) 1990-03-02
PL156798B1 (pl) 1992-04-30
FI901087A7 (fi) 1990-03-02
NO901016L (no) 1990-05-02
EP0306251A3 (en) 1990-08-01
HU204832B (en) 1992-02-28
PT88407A (pt) 1989-07-31
YU46863B (sh) 1994-06-24
IL87590A (en) 1992-07-15
DK488688A (da) 1989-04-07
AU2184188A (en) 1989-03-09
KR900008841B1 (ko) 1990-11-30
MY103765A (en) 1993-09-30
MX12896A (es) 1993-06-01
WO1989001775A1 (en) 1989-03-09
DK488688D0 (da) 1988-09-02
CN1022325C (zh) 1993-10-06
HUT56106A (en) 1991-07-29
FI901087A0 (fi) 1990-03-02
EP0306251A2 (en) 1989-03-08
PH24957A (en) 1990-12-26
ZA886507B (en) 1990-04-25
CN1031702A (zh) 1989-03-15
CS273186B2 (en) 1991-03-12
YU167788A (en) 1990-06-30
EG18591A (en) 1993-06-30
JPH0583554B2 (enExample) 1993-11-26
DD273381A5 (de) 1989-11-15
IL87590A0 (en) 1989-01-31

Similar Documents

Publication Publication Date Title
US4980357A (en) Azolidinedione derivatives
EP0264586B1 (en) Hydantoin derivatives for treating complications of diabetes
EP0034063B1 (en) Hydantoin amines and pharmaceutical compositions thereof
EP0401981B1 (en) Pyridazinone deriratives
KR850001228B1 (ko) 치환 인돌린-2-온 유도체의 제조방법
JPH0825877B2 (ja) 眼科治療用組成物
US4940708A (en) 4-arylsulfonyl-3,4-dihydro-2(1H)-quinoxalinone-1-alkanoic acids, esters, and salts
US5011840A (en) Imidazolidinedione derivatives in diabetes treatment
EP0014079B1 (en) Spiro-quinolylhydantoins, process for their preparation and pharmaceutical compositions thereof
KR860001581B1 (ko) 스피로-3-헤테로-아졸론의 제조방법
EP0306251A2 (en) Azolidinedione derivatives
KR860000486B1 (ko) 옥사졸리딘디온 유도체의 제조 방법
CA1226866A (en) Hydantoin derivatives
US4193996A (en) Spiro-quinolone hydantoins
NZ226030A (en) Spiro-azolone derivatives; pharmaceutical compositions
FI83322B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 7',8'-dihydro-spiro/imidazolidin-4,5'-kinolin/ -2,5-dionderivat.
FI80682C (fi) Foerfarande foer framstaellning av aldosreduktas inhibears 5-(2-alkoxi-3-substituerad fenyl)hydantoiner.
JPH08277266A (ja) スピロ三環式芳香族スクシンイミド誘導体、並びにヒト及び動物の糖尿病合併症治療剤